PITTSBURGH, May 8, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced positive results of its Phase 3 study (NCT05139121) evaluating the contraceptive ...
The Company expects to submit the New Drug Application for Xulane Lo in the second half of 2025. A low dose combination hormonal patch was found to be effective for pregnancy prevention based on ...
Pharmaceutical giant Johnson & Johnson may have known years ago about the deadly risks of its birth control patch Ortho Evra, according to internal documents obtained by NBC News. Patient reports ...
WASHINGTON - Risks of blood clots in legs and lungs are twice as high for women using the birth control patch instead of the pill, says a study reported by the drug maker and the Food and Drug ...
Mar. 23 -- FRIDAY, Jan. 18 (HealthDay News) -- A birth control skin patch used by many American women carries a risk of serious blood clots that is higher than the risk already recognized for the ...
December 9, 2011 — Voting in favor of the norelgestromin/ethinyl estradiol transdermal contraceptive patch (Ortho Evra, Jannsen), a US Food and Drug Administration (FDA) advisory panel today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results